EDIT Editas Medicine

Editas Medicine Receives HREC/CTN Approval to Initiate Phase 1/2 Strive Trial of EDIT-401

Editas Medicine received regulatory and ethics approval to initiate the Phase 1/2 Strive trial of EDIT-401 in Australia (with submission in New Zealand). The company remains on track to begin patient dosing in 2026 and report initial safety and tolerability data in Q1 2027, with topline safety and efficacy data later in 2027.

Editas Medicine Presents EDIT-401 Preclinical Data at EAS Congress

Editas presented new NHP data showing single-dose EDIT-401 achieved ≥90% mean reductions in LDL-C, Lp(a), and ApoB. The company received positive pre-IND FDA feedback and plans to submit a CTN in Australia by mid-2026 to start first-in-human trials in HeFH patients, with early human proof-of-concept data expected by end of 2026.